Search results
S2 Episode 3: How Do You Treat Refractory Colorectal Cancer?
Medscape· 3 days agoFor more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify,...
Pierre Fabre Laboratories Announce IND Filing for PFL-002/VERT-002, a Potential Treatment for...
KETK· 3 days agoPierre Fabre Laboratories today announced the filing of an investigational new drug ("IND") application to the U.S. Food and Drug Administration ("FDA") to initiate a first-in-human (FIH) Phase ...
Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals
Zacks via Yahoo Finance· 3 days agoAnnexon (ANNX) jumps 31% after meeting the primary and key secondary endpoints with the low dose of...
Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of...
KOIN News 6 Portland· 5 days agoInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 7 days agoAn additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacySYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in mUC and 43% ORR and 86% DCR in cervical cancer to date at doses
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with...
Clearfield Progress· 7 days agoKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the presentation of updated exploratory subgroup analyses ...
Qilu Pharmaceutical's Three Clinical Studies on Cancer Immunotherapy Presented at ASCO 2024
FOX 16 Little Rock· 1 day agoThe 2024 American Society of Clinical Oncology (ASCO) Annual Meeting convened from May 31 to June 4, 2024 in Chicago, USA, adopting a hybrid format. Among the presented works, three clinical ...
Arrivent Biopharma enters into cancer drug development collaboration valued at up to $615M -...
The Business Journals· 3 days agoAntibody drug conjugates, or ADCs, are a type of cancer treatment that combines a monoclonal ...
Inebilizumab 'MITIGATES' Flare Risk in IgG4-Related Disease
Medscape· 1 day agoInebilizumab-cdon reduced the risk for flares by 87% in patients with IgG4-RD, the MITIGATE study showed.
Stocks making the biggest moves midday: Five Below, Salesforce, Lululemon, Instacart and more
CNBC· 2 days agoCheck out the companies making headlines in midday trading: Five Below — Shares of Five Below sank...